Vaccine supply shortage comes at a bad time, as African countries make headway with their outbreaks and have seen good uptake ...

RSV, meningococcal, and chikungunya vaccine recommendations from the previous ACIP panel are now official policy.

Danish vaccine specialist Bavarian Nordic (OMX: BAVA) is set to collect $160 million from the sale of a US priority review voucher (PRV) earned through the approval of its chikungunya vaccine, ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one dose. By combining two immune-boosting adjuvants alum ...

The UK’s Commission on Human Medicines has temporarily restricted the use of the IXCHIQ chikungunya vaccine in people aged over 65 while officials review global reports of very rare fatal reactions.

COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of ...

As for Bavarian Nordic, the vaccine specialist is differentiating itself from rival Valneva not only when it comes to PRV sale prices. In May, the FDA and the CDC recommended a pause in the use of ...

It was only in February 2024 that Valneva monetized a PRV obtained from the FDA approval of the U.S.’s first approved chikungunya vaccine, Ixchiq, for $103 million. The general understanding at ...

Bavarian Nordic was awarded the PRV in February 2025, following the approval by the U.S. Food and Drug Administration of the chikungunya vaccine, VIMKUNYA for prevention of disease caused by ...